Curated News
By: NewsRamp Editorial Staff
August 29, 2024
Aclarion Expands CLUE Trial to New Jersey with Dr. Justin Kubeck Joining the Network of Surgeons
Discuss on Reddit
Discuss on SubstackTLDR
- Participating in the CLUE Trial can provide surgeons with valuable real-world evidence to drive early payer coverage decisions.
- Aclarion's Nociscan leverages biomarkers and AI algorithms to help physicians distinguish between painful and nonpainful discs in the lumbar spine.
- Nociscan's AI-generated data can improve the treatment of chronic low back pain, positively impacting the lives of 266 million people globally.
- Dr. Kubeck will initiate the CLUE Trial in New Jersey at Ocean Pain and Spine, bringing valuable insights to the healthcare industry.
Impact - Why it Matters
This news matters as it highlights the potential impact of Nociscan's AI data on the initial treatment plan for patients with chronic low back pain. It also emphasizes the importance of real-world evidence in driving early payer coverage decisions for emerging diagnostic tools.
Summary
Aclarion, Inc., a healthcare technology company, announced the expansion of the multi-center CLUE Trial to New Jersey, with Dr. Justin Kubeck joining an expanding network of spine surgeons participating in the trial. The trial aims to identify how often Nociscan's AI data changes the initial treatment plan for patients with chronic low back pain. Nociscan is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine, providing critical insights into the location of a patient’s low back pain.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, Aclarion Expands CLUE Trial to New Jersey with Dr. Justin Kubeck Joining the Network of Surgeons
